Abstract
To report long-term outcomes in terms of health-related quality of life (HRQoL) and survival of a dose-escalating radiotherapy protocol and to validate a new disease-specific HRQoL instrument. 189 consecutive men with prostate cancer were analyzed; 127 patients had T1-2 (1% T1, 66% T2) and 62 patients (33%) T3 tumors. The pelvic lymphatics were treated to a dose of 50 Gy by external-beam irradiation. The prostate dose was limited to 40 Gy using compensators. The prostate was treated to the total nominal dose of 70 Gy using high-dose-rate (HDR) brachytherapy. The fraction dose was 15 Gy in the McNeal zone (planning target volume [PTV] 1), while 8-9 Gy were applied in the entire prostate (PTV 2). The HRQoL of the 145 long-term survivors was assessed using the EORTC QLQ-C30 and a new prostate-specific instrument (PSM-G 1.0). The reliability of the instruments used and HRQoL scale scores were calculated. Uni-/multivariate analyses of variance were performed. At a mean follow-up of 6.5 years 86.3% of the patients were disease-free, and 78% were biochemically controlled. The mean Cronbach's alpha-values were 0.81 for the QLQ-C30, and 0.74 for the prostate-specific module. Univariate analyses of variance by T-stage, grading, prostata-...Continue Reading
Citations
Jul 4, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Víctor Macías, Albert Biete
Sep 11, 2013·Nature Reviews. Urology·Nicholas G ZaorskyRobert B Den
Nov 9, 2012·The British Journal of Radiology·A ChallapalliS A Mangar
Jan 19, 2010·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Hans GeinitzFrank B Zimmermann
Jul 23, 2011·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Masoud Bahrami, Paul Arbon
Feb 25, 2011·Brachytherapy·George HrubyMartin R Stockler
May 15, 2007·International Journal of Radiation Oncology, Biology, Physics·Thomas WahlgrenYvonne Brandberg
Mar 31, 2012·Journal of Advanced Nursing·Eilis Mc CaughanHugh McKenna
Nov 16, 2013·Cancer Treatment Reviews·Nicholas G ZaorskyRobert B Den
Jun 28, 2016·Cancer Treatment Reviews·Nicholas G ZaorskyEric M Horwitz
May 12, 2017·Health and Quality of Life Outcomes·Marieke van LeeuwenUNKNOWN and the NCRN Testis Clinical Studies Group
Oct 6, 2007·Acta Oncologica·Karl Mikael KälknerSten Nilsson
Jul 1, 2017·Nature Reviews. Urology·Nicholas G ZaorskyEric M Horwitz
Aug 30, 2006·Acta Oncologica·Dirk VordermarkMichael Flentje
Oct 16, 2013·Expert Review of Anticancer Therapy·Nicholas G ZaorskyRobert B Den
Nov 8, 2013·Expert Review of Medical Devices·Nicholas G ZaorskyMark D Hurwitz
Mar 15, 2014·Physics in Medicine and Biology·Jinqin AiQian Liu
Jan 11, 2020·Frontiers in Oncology·Benjamin W Fischer-ValuckJeff M Michalski